07:00 , Jun 27, 2016 |  BC Week In Review  |  Company News

Adaptive Biotechnologies, Argos deal

The companies partnered to study immune responses induced by Argos’ AGS-003 and AGS-004 immunotherapies. Adaptive will use its immunoSEQ platform, a high throughput T and B cell receptor sequencing technology, to characterize immune...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Company News

Argos, Chongqing Lummy Pharmaceutical deal

Argos granted Chongquing Lummy’s Lummy Co. Ltd. subsidiary exclusive rights in China, including Hong Kong and Macau, and Taiwan to develop and commercialize AGS-003 for oncology indications. Argos is conducting the Phase III ADAPT...
02:18 , Apr 15, 2015 |  BC Extra  |  Company News

Lummy gains Chinese rights to Argos' AGS-003

Argos Therapeutics Inc. (NASDAQ:ARGS) granted the Lummy Co. Ltd. subsidiary of Chongqing Lummy Pharmaceutical Co. Ltd. (SZSE:300006) development and commercialization rights in greater China for AGS-003 in oncology indications. Argos is conducting a Phase III...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Clinical News

AGS-004: Phase IIb data

Top-line data from a double-blind, North American Phase IIb trial in 54 patients with chronic HIV-1 infection showed that AGS-004 missed the primary endpoint of a ³1.1 log reduction in viral load after the 12-week...
08:00 , Jan 9, 2015 |  BC Extra  |  Clinical News

Argos falls on Phase IIb miss in HIV

Argos Therapeutics Inc. (NASDAQ:ARGS) plunged $3.10 (32%) to $6.51 on Friday after reporting that AGS-004 missed the primary endpoint of a 1.1 log reduction in median viral load after 12 weeks of antiretroviral therapy interruption...
07:00 , Jun 24, 2013 |  BioCentury  |  Regulation

Of cures & co-morbidities

The second meeting under FDA's Patient-Focused Drug Development initiative has raised a conundrum for the agency and HIV companies. As the HIV population grows older and has more age-related co-morbidities, the need for drugs that...
07:00 , Mar 12, 2012 |  BioCentury  |  Finance

Argos plowing ahead

Argos Therapeutics Inc. is being coy about its financing plans after withdrawing its planned IPO on NASDAQ due to market conditions. But the company says it is going ahead next quarter with a $40-$50 million...
01:42 , Mar 7, 2012 |  BC Extra  |  Financial News

Argos pulls IPO

Cancer immunotherapy company Argos Therapeutics Inc. (Durham, N.C.) withdrew its planned IPO citing market conditions. The company had planned to sell 5.3 million shares at $13-$15 per share. A $14 price would have raised $73.5...
01:40 , Feb 17, 2012 |  BC Extra  |  Financial News

Argos sets IPO range

Argos Therapeutics Inc. (Durham, N.C.) amended its IPO and now plans to sell 5.3 million shares at $13-$15 per share. A $14 price would raise $73.5 million and value the company at $215.2 million. Lazard;...
23:46 , Jul 29, 2011 |  BC Extra  |  Financial News

Argos files for IPO

Argos Therapeutics Inc. (Durham, N.C.) filed to raise up to $86.3 million in an IPO underwritten by Lazard; Canaccord; Needham; and BMO Capital Markets. Argos' is developing autologous dendritic cell immunotherapy candidates AGS-003 and AGS-004....